5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Topical Insulin-Utility and Results in Refractory Neurotrophic Keratopathy in Stages 2 and 3.

          The purpose of this study was to evaluate the clinical outcome of patients with refractory neurotrophic keratopathy (NK) in stages 2 and 3 treated with topical insulin.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Long-term restoration of corneal sensitivity in neurotrophic keratopathy after rhNGF treatment

              Bookmark
              • Record: found
              • Abstract: not found
              • Book: not found

              Neuroparalytic keratitis

                Bookmark

                Author and article information

                Journal
                COP
                COP
                10.1159/issn.1663-2699
                Case Reports in Ophthalmology
                S. Karger AG
                1663-2699
                2022
                May - August 2022
                31 August 2022
                : 13
                : 2
                : 663-670
                Affiliations
                [_a] aAiken Ophthalmology Clinic, Aiken Foundation, and Service of Ophthalmology, Hospital Universitari i Politècnico La Fe, Valencia, Spain
                [_b] bService of Ophthalmology, Hospital Punta de Europa, Algeciras, Spain
                Author information
                https://orcid.org/0000-0002-5241-0066
                https://orcid.org/0000-0002-8697-9883
                Article
                525923 PMC9459538 Case Rep Ophthalmol 2022;13:663–670
                10.1159/000525923
                PMC9459538
                36160492
                e0ccc58b-83e5-4a1b-8635-6141f2bb8571
                © 2022 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.

                History
                : 18 May 2022
                : 25 June 2022
                Page count
                Figures: 4, Pages: 8
                Funding
                Funding support was provided by Dompé Farmaceutici SpA, Milan, Italy.
                Categories
                Case Report

                Vision sciences,Ophthalmology & Optometry,Pathology
                Neurotrophic keratopathy,Cenegermin,Recombinant human nerve growth factor

                Comments

                Comment on this article